Jan J Verschuuren Selected Research

musk

1/2021	Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis.
1/2019	MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity.
1/2019	Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.
1/2018	IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders.
11/2017	A prospective, placebo controlled study on the humoral immune response to and safety of tetanus revaccination in myasthenia gravis.
2/2016	Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity.
1/2016	Myasthenia gravis with muscle specific kinase antibodies mimicking amyotrophic lateral sclerosis.
10/2015	Myasthenia gravis: subgroup classification and therapeutic strategies.
12/2013	MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4.
12/2012	Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jan J Verschuuren Research Topics

Disease

11	Myasthenia Gravis 01/2021 - 04/2012
10	Muscle Weakness 01/2021 - 03/2002
7	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 11/2008
6	Lambert-Eaton Myasthenic Syndrome (Lambert-Eaton Syndrome) 01/2019 - 07/2003
5	Neoplasms (Cancer) 01/2021 - 07/2003
4	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 01/2016 - 12/2011
3	Opsoclonus-Myoclonus Syndrome (Kinsbourne Syndrome) 01/2021 - 12/2002
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2019 - 09/2003
2	Body Weight (Weight, Body) 01/2019 - 04/2011
2	Paralysis (Palsy) 04/2012 - 05/2008
2	Muscular Dystrophies (Muscular Dystrophy) 04/2011 - 12/2007
2	Breast Neoplasms (Breast Cancer) 09/2005 - 12/2002
1	Paraneoplastic Cerebellar Degeneration 01/2019
1	Nervous System Diseases (Neurological Disorders) 01/2019
1	Inflammation (Inflammations) 01/2018
1	Tetanus 11/2017
1	Cardiomyopathies (Cardiomyopathy) 01/2017
1	Scoliosis 01/2017
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2016
1	Muscular Atrophy (Muscle Atrophy) 01/2016
1	Fatigue 10/2015
1	Thymoma (Thymic Carcinoma) 10/2015
1	Polyneuropathies (Polyneuropathy) 01/2009
1	Myotonia 08/2008
1	Respiratory Paralysis 05/2008
1	Guillain-Barre Syndrome 05/2008
1	Miller Fisher Syndrome (Fisher Syndrome) 05/2008
1	Narcolepsy 05/2006
1	Neoplasm Metastasis (Metastasis) 09/2005
1	Adenocarcinoma 12/2002
1	Disease Progression 03/2002
1	Inclusion Body Myositis 03/2002

Drug/Important Bio-Agent (IBA)

13	AntibodiesIBA 01/2021 - 05/2008
11	AutoantibodiesIBA 01/2021 - 05/2006
10	muskIBA 01/2021 - 12/2012
9	Immunoglobulin G (IgG)IBA 01/2021 - 04/2012
8	Phosphotransferases (Kinase)IBA 01/2021 - 04/2012
8	Proteins (Proteins, Gene)FDA Link 01/2019 - 09/2005
5	Cholinergic ReceptorsIBA 01/2019 - 04/2012
5	DystrophinIBA 01/2016 - 12/2007
2	AgrinIBA 01/2019 - 10/2015
2	Pharmaceutical PreparationsIBA 01/2019 - 10/2015
2	Antisense OligonucleotidesIBA 04/2011 - 12/2007
2	PRO051IBA 04/2011 - 12/2007
2	Calcium Channels (Calcium Channel)IBA 11/2010 - 11/2008
2	GangliosidesIBA 01/2009 - 05/2008
1	neonatal Fc receptorIBA 01/2019
1	Monoclonal AntibodiesIBA 01/2019
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2017
1	EpitopesIBA 02/2016
1	Lipoproteins (Lipoprotein)IBA 10/2015
1	CortactinIBA 10/2014
1	AntigensIBA 10/2014
1	Complement System Proteins (Complement)IBA 12/2013
1	LipidsIBA 09/2013
1	myasthenia gravis anti-skeletal muscle antibody (ASMA)IBA 12/2012
1	Acetylcholine (Acetylcholine Chloride)FDA Link 04/2012
1	Immunoglobulins (Immunoglobulin)IBA 04/2012
1	Nitric Oxide Synthase Type I (Neuronal Nitric Oxide Synthase)IBA 12/2011
1	Dystroglycans (Dystroglycan)IBA 12/2011
1	Messenger RNA (mRNA)IBA 04/2011
1	Cholinergic Agents (Cholinergics)IBA 11/2010
1	AmifampridineIBA 11/2010
1	Immunoglobulin M (IgM)IBA 01/2009
1	Chloride Channels (Chloride Channel)IBA 08/2008
1	N-desmethylstobadineIBA 08/2008
1	eculizumab FDA Link 05/2008
1	OrexinsIBA 05/2006
1	TrypsinIBA 09/2005
1	Peptides (Polypeptides)IBA 09/2005
1	HLA-B8 Antigen (HLA B8 Antigen)IBA 09/2003
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2003
1	Interleukin-10 (Interleukin 10)IBA 07/2003
1	ANNA-2 antibodyIBA 12/2002
1	Methotrexate (Mexate)FDA LinkGeneric 03/2002
1	Creatine Kinase (Creatine Phosphokinase)IBA 03/2002

Therapy/Procedure

1	Injections 01/2019
1	Subcutaneous Injections 04/2011
1	Intravenous Injections 05/2008
1	Intraperitoneal Injections 05/2008
1	Intramuscular Injections 12/2007